Skip to main content
TipRanks
Go Ultimate75% OFF

ARS Pharmaceuticals (SPRY) Q3 2026 Earnings Report

593 Followers

SPRY Q3 2026 EPS Results

Actual EPS
-$0.36
Consensus EPS
-$0.31
Beat/Miss
Missed by -$0.05
One Year Ago EPS
-$0.52

SPRY Q3 2026 Revenue Results

Actual Revenue
$37.71M
Expected Revenue
$41.99M
Beat/Miss
Missed by -$4.28M
YoY Revenue Growth
+16.03%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/05/2026
Time
After Close
Conference Call
Thursday, November 5, 2026
SPRY Upcoming Earnings

ARS Pharmaceuticals's next earnings date is estimated for March 25, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

SPRY Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 05, 2026|% Change Since:35.47%|
Earnings Call Sentiment|Positive

The call was predominantly positive, with strong year-over-year gains in neffy demand, market share, prescribers, and field-targeted accounts, alongside a more than 40% reduction in SG&A and a reaffirmed path to cash flow breakeven by year-end 2027. The company also reported progress for ARS-2 and described multiple commercial and payer initiatives. Challenges include entrenched prescribing behavior, prior authorization-related prescription-to-fill losses, remaining coverage gaps, unmet need in chronic spontaneous urticaria, and quarterly revenue effects from inventory changes.

Company Guidance

Management affirmed it is on track to achieve cash flow breakeven by year-end 2027, with operating spending kept within the second half 2026 guidance of $114 million to $126 million in aggregate SG&A and R&D expenses, including stock-based compensation, SG&A reduced by more than 40% in the second half of the year versus the first half and the lower SG&A run rate sustained through 2027; gross to net is in and around 50%, with continued increase year-over-year in field targeted market share and steady year-over-year market share gains through targeted provider engagement. The commercial reset is expected to be operationally rolled out over the next quarter, with financial benefits increasingly visible through the first half of 2027, a new marketing campaign expected to roll out in early 2027, and interim data from the ARS-2 Phase 2b trial evaluating 0.5 milligram and 1 milligram doses expected in the first quarter of 2027, with full data expected later in 2027; the company plans to provide its full year 2027 financial outlook when it reports fourth quarter results.

  • Neffy Revenue, Market Share, and Demand GrowthNeffy generated $33.4 million in U.S. net product revenue in the third quarter. Total U.S. market share surpassed 5%, up from 4% in the third quarter of 2025, driven by a 42% year-over-year increase in neffy end user demand.
  • Expansion of Prescriber BaseNeffy had more than 19,000 unique prescribers in the third quarter, up 49% year-over-year, bringing the total number of prescribers since launch to nearly 45,000.
  • Strong Performance in Field-Targeted AccountsMarket share in field-targeted accounts, representing about 44% of the total market opportunity, increased from 6% in Q3 2025 to 9% in Q3 2026, compared with 2% in non-targeted accounts.
  • Total Revenue IncreaseThird-quarter total revenue was $37.7 million, including $33.4 million in U.S. neffy net product revenue, $2.6 million in ex-U.S. supply revenue, and $1.7 million in collaboration revenue. This compared with total revenue of $32.5 million in the third quarter of 2025, including $31.3 million in net product revenue.
  • SG&A Reduction and Financial DisciplineThird-quarter operating expenses were in line with guidance. SG&A expenses were $43.5 million, down more than 40% compared with the first-half 2026 quarterly average, driven largely by discontinuing linear TV, reducing broad consumer advertising, and making more targeted commercial investments.
  • Path to Cash Flow Breakeven MaintainedThe company affirmed that it remains on track to achieve cash flow breakeven by year-end 2027 and plans to sustain the lower SG&A run rate through 2027. Gross-to-net was described as in and around 50%, which management said supports the long-term year-end 2027 cash flow breakeven outlook.
  • ARS-2 Phase 2b Trial ProgressingThe Phase 2b trial of ARS-2 for breakthrough flares in chronic spontaneous urticaria is progressing, with interim data expected in the first quarter of 2027. The trial is evaluating 0.5 milligram and 1 milligram doses to identify the minimum effective dose.
  • Positive Prior ARS-2 Phase 2 ResultsResults from the completed Phase 2 trial showed that ARS-2 improved both itch and hives scores, beginning as early as 5 minutes after dosing.
  • Expansion of Needle-Free Delivery PlatformThe company stated that ARS-2 could expand its needle-free delivery platform beyond anaphylaxis and potentially become the first FDA-approved on-demand treatment for breakthrough flares in chronic spontaneous urticaria, including in patients on biologics. A one-time $12.5 million payment under a license agreement supports this platform expansion.
  • Commercial Strategy Reset and Targeted Provider EngagementARS is implementing a unified commercial strategy focused on where it engages, what it says, and how it converts prescriptions into fills. The company is moving to an account-based sales approach that engages prescribers, advanced practice providers, nurses, office staff, and personnel responsible for electronic prescriptions, refill protocols, and prior authorizations.
  • Planned Commercial Campaign and Market Access InitiativesA new marketing campaign is expected to roll out in early 2027. The company is also actively engaging remaining Medicaid states and commercial plans to expand neffy access, while using submitted prior authorizations to document demand with payers.
  • Broad Existing Commercial CoverageManagement stated that more than 80% of commercial lives are currently covered for neffy, although some plans require prior authorization.
  • New Senior Leadership AppointmentsARS appointed Dr. Randall Kaye as Chief Medical Officer, John Slebir as Chief Legal Officer, and Meg Smith as Chief Commercial Officer. Management highlighted their medical, legal, commercial, and business experience.
  • Cash Position and Nondilutive Capital AccessThe company ended the third quarter with $138.4 million in cash, cash equivalents, and short-term investments. Management also said it accessed term-loan capital because it viewed the terms as attractive and described the capital as nondilutive.

SPRY Earnings History

SPRY earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 25, 20272026 (Q4)-0.28--0.41――
Nov 05, 20262026 (Q3)-0.30-0.36-0.5230.77% (+0.16)
Aug 13, 20262026 (Q2)-0.48-0.63-0.46-36.96% (-0.17)
May 15, 20262026 (Q1)-0.52-0.61-0.35-74.29% (-0.26)
Mar 09, 20262025 (Q4)-0.43-0.410.48-185.42% (-0.89)
Nov 10, 20252025 (Q3)-0.45-0.52-0.2-160.00% (-0.32)
Aug 13, 20252025 (Q2)-0.46-0.46-0.13-253.85% (-0.33)
May 14, 20252025 (Q1)-0.34-0.35-0.11-218.18% (-0.24)
Mar 20, 20252024 (Q4)-0.240.48-0.07785.71% (+0.55)
Nov 13, 20242024 (Q3)-0.14-0.20-0.16-25.00% (-0.04)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed